about
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraRelapsed Hodgkin lymphoma: management strategiesMantle cell lymphoma in relapse: the role of emerging new drugs.New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes.Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.Peripheral T-cell lymphoma: time for a T-cell-centric standard of care.Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerImmune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologistLysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survivalMonomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disordersMisdiagnosis of non-hodgkin lymphoma as multiple myelomaTargeting CD30 in hodgkin lymphoma: antibody-drug conjugates make a differenceImmunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific AntibodiesSurvival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraCART19 in Hodgkin lymphoma: are we driving the right model?New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaAuthor Correction: The bone marrow microenvironment at single-cell resolutionAn evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphomaPolatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)Advances in Therapy for Relapsed or Refractory Hodgkin LymphomaThe bone marrow microenvironment at single-cell resolutionCheckpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
P50
Q28078774-6AD89D9F-AFF1-41FD-BA9D-E5B16FA3256AQ33427510-82F2E4E7-5C25-4696-AC14-71B926AAACA0Q35009005-735876C9-D76E-4B04-A9F5-E7DF8E656D74Q36939926-C55C2A47-EF6C-4FC3-9EC5-8BFD88EB7517Q37008427-CBF8D7B7-11D0-4B7E-9CF4-FF7304879090Q37777298-9A8CDFF1-9D0E-43CA-804B-18C4E0F65C3AQ38085250-23960153-EE5D-4A98-83F4-6F1194DF5B29Q38115232-CC84F8FE-0223-406F-A152-56E8D1DBD41DQ38583348-7FE27AAD-2C30-4881-869E-65A93CE06353Q38775871-8891C920-678F-440F-991E-264A3537D314Q40422243-C2577F19-CF21-4851-94C2-E31095543B8FQ42921960-0DBEF3F1-7868-4404-9471-C2543D6F931CQ46299501-EBE5ED2A-0245-46C8-8C08-9AD2ECA74B6CQ46616110-8B52E00B-506D-486E-85EE-385D387CAD04Q48229580-E6CE78DB-2310-40CF-A1C8-FCF512F365F0Q48295024-038A3A1B-8EE2-41A2-9592-4E3E9A1D63FEQ52562955-DAC00577-097F-4BEC-92E6-1481B414BABCQ57975577-BDAA4964-52B9-433B-AC23-46F416FA5DE0Q64069464-BB2F3C07-B0F9-4D13-9AAD-ADDF15E869ACQ80195184-CFCC4679-1326-44ED-8D69-18E07568764FQ84969958-86F5E31B-79A2-4EAC-BAE7-C01E10A0E155Q85312888-433D8DCC-E437-4192-98BA-1B2A2D0B7C44Q87145047-055E6086-8A54-490D-9E89-AB8A43BAFBD9Q89047127-7465FC72-7A2D-45AF-B454-D33C3974F1BEQ90921413-28DA7863-142A-4922-87B5-28569FA6597BQ91321548-81C4EC22-9ED2-4566-8719-599416153399Q91546469-776E55FA-BDED-4CB2-9D17-AD5B69C867FBQ91806851-E4A89DCC-8E96-48C7-B85D-C1C7E754B65EQ91810142-53E3F541-2085-4FEE-9B9A-BEC8EB250D14Q92742003-4E2BBB33-5BF4-4B2E-B574-7CA158ED8C5CQ92763983-4036862A-F509-46CF-82D2-3539C4BF202CQ92934524-A98F161C-8E3B-4B26-ABE7-6D8C1EE691D4Q93012764-9C2F0F76-403B-49E7-802D-F3DC1983356DQ95280477-BFD93EDB-099E-477B-B7AA-3482AD5D0848
P50
description
researcher ORCID ID = 0000-0003-1116-3246
@en
wetenschapper
@nl
name
Catherine S.M. Diefenbach
@ast
Catherine S.M. Diefenbach
@en
Catherine S.M. Diefenbach
@es
Catherine S.M. Diefenbach
@nl
type
label
Catherine S.M. Diefenbach
@ast
Catherine S.M. Diefenbach
@en
Catherine S.M. Diefenbach
@es
Catherine S.M. Diefenbach
@nl
prefLabel
Catherine S.M. Diefenbach
@ast
Catherine S.M. Diefenbach
@en
Catherine S.M. Diefenbach
@es
Catherine S.M. Diefenbach
@nl
P106
P21
P31
P496
0000-0003-1116-3246